Market Outlook

Treatment for recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) has remained relatively unchanged in the past ten years, and Erbitux-based regimens continue to be the mainstay of treatment. However, immune checkpoint inhibitors are revolutionizing the treatment algorithm for this patient population with the 2016 / 2018 approvals of Merck & Co.’s Keytruda and Bristol-Myers Squibb / Ono Pharmaceutical’s Opdivo for previously treated recurrent or metastatic SCCHN. Although SCCHN has historically proved to be a complex challenge for drug developers, many immune-oncology approaches and other drug classes are competing in late-phase development for SCCHN, both in the metastatic setting and in earlier stages of the disease. Several agents are being positioned for the untapped and lucrative locoregionally advanced SCCHN setting and are also poised to contribute to the robust market growth over the 2018-2028 forecast period.

Questions Answered

  • How large are the clinically and commercially relevant drug-treatable SCCHN populations, and how will drug-treatment rates change over time?
  • What is the current state of treatment for recurrent or metastatic SCCHN? What are interviewed experts’ views on these therapies?
  • Which pipeline products are poised to become options for the treatment of SCCHN, and what sales / uptake could they secure?
  • What are the key drivers and constraints in the SCCHN market, and how will the major markets evolve over the ten-year forecast period?

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • Key Findings
      • SCCHN - Key Findings
    • Key Updates
      • October 2019
      • September 2019
      • June 2019
      • December 2018
    • Market Outlook
      • Key Findings
        • Market Overview
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for SCCHN?
        • What Factors Are Constraining the Market for SCCHN?
      • Segment-Specific Trends
        • Locoregionally Advanced: Stage III, IVA, IVB
        • First-Line Recurrent or Metastatic SCCHN
        • Second- and Third-Line Recurrent or Metastatic SCCHN
    • Forecast
    • Etiology and Pathophysiology
      • Disease Overview
      • Disease Pathophysiology
        • Anatomy, Development, and Progression of SCCHN
        • Risk Factors Associated with SCCHN
      • Staging and Classification
        • Clinical Staging of SCCHN
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Incident Cases of SCCHN
        • Stage Distribution of SCCHN
        • Recurrent Incident Cases of SCCHN
        • Drug-Treatable Populations
        • Drug-Treated Populations
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • EGFR Inhibitors
        • Immune Checkpoint Inhibitors
      • Medical Practice
        • Early-Stage Localized (Stage I/II) SCCHN
        • Locoregionally Advanced (Stage III/IVA/IVB) SCCHN
        • First-Line Recurrent or Metastatic SCCHN
        • Second- and Third-Line Recurrent or Metastatic SCCHN
        • Treatment Guidelines
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in SCCHN
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Immune Checkpoint Inhibitors
        • T-Cell-Based Immunotherapy
        • Cytokine-Based Immunotherapy
        • Photoimmunotherapy
      • Early-Phase Pipeline Analysis
    • Access and Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Market Forecast Assumptions File
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug- and Regimen-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Cycles of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • SCCHN Bibliography

Author(s): Laura Vinuesa, DVM, MSc; Atul Sharma, MPH; Ann-Marie Looney, M.Sc., Ph.D

Laura Vinuesa, DVM, is a Senior Business Insights Analyst in the Oncology Division at Decision Resources Group, with expertise in thyroid carcinoma and bladder cancer. Previously, Dr. Vinuesa was an EU Market Access Analyst in the Global Market Access Insights Team at Decision Resources Group. She has expertise in market access, pricing and reimbursement, health technology assessment, and health policy. Prior to joining Decision Resources, she worked as Market Access & Institutional Relations Analyst at Pfizer in Spain, providing support for the successful market launch of drugs for different areas: cardiovascular, oncology, mental disorder and rare disease. She is a Doctor of Veterinary Medicine from the Complutense University of Madrid, and holds a in Clinical Research and Pharmaceutical Medicine from EPHOS - School of PharmaStudies. lvinuesa@

Atul Sharma started working in Decision Resources Group as an intern in early 2016 and currently works as an associate epidemiologist. He performs fully documented systematic reviews of both published and grey literature on the epidemiology of assigned diseases and their risk factors to estimate incidence/prevalence over a 10-30 year period. He produces analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets. He holds a Master’s in Public Health degree from School of Public Health, Post-Graduate Institute of Medical Education and Research and a Bachelor’s in dental surgery from MN DAV Dental College & Hospital.

Ann-Marie Looney, is a Business Insights Analyst in the oncology team at Decision Resources Group. Prior to joining DRG, Dr Looney worked as a postdoctoral researcher for the National Children’s Research Centre and the Irish Centre for Fetal and Neonatal Translational Research, Ireland where her work centred on the discovery and validation of biomarkers of early childhood injury and disease, with a specific focus on early childhood obesity, neonatal brain injury and autism spectrum ; She has a in Neuroscience, a by research in molecular biology and a in clinical and translational research from University College Cork, Ireland.


Related Reports

Squamous Cell Carcinoma of the Head and Neck | Unmet Need | Detailed, Expanded Analysis: Recurrent or Metastatic Non-Nasopharyngeal SCCHN (US/EU)

Treatment of recurrent or metastatic non-nasopharyngeal squamous cell carcinoma of the head and neck (SCCHN) has remained relativ...

View Details

Squamous Cell Carcinoma of the Head and Neck | Disease Landscape and Forecast | G7 | 2018

Market Outlook: Squamous cell carcinoma of the head and neck (SCCHN) is an anatomically and biologically heterogeneous disease that has historically proven to be a complex...

View Details